Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Is SOD's Contribution to Lou Gehrig’s Disease Unfolding?
6 June 2003. Mutations in the enzyme Cu/Zn superoxide dismutase (SOD) have been linked to about 20 percent of familial cases of amyotrophic lateral sclerosis (ALS), but there is no explanation yet for how the mutations contribute to ALS pathology. An extensive investigation of purified SOD in vitro, published in the June 3 PNAS Early Edition, suggests that the mutations interfere with protein folding.

There are a number of theories of how SOD mutations could lead to the death of motor neurons, including increased oxidative damage (see related news story) and disruption of axonal transport (see ARF related news story). There is also the matter of the abnormal SOD aggregates-these are found in neurons and glia in the familial, but not the sporadic cases-suggesting to some researchers that familial ALS might be a protein conformational disorder (e.g., prion disease), in which misfolded proteins form potentially toxic aggregates (see ARF related news story).

In all, more than 90 SOD mutations have been correlated with ALS, and many have been introduced to mice, where they produce abnormal SOD aggregates prior to the appearance of other cellular pathology characteristic of ALS in humans. Among the theories put forward to explain this effect of the mutations is that they interfere with proper folding of SOD.

Relatively little is known about the intrinsic properties of SOD protein, and Meiering and colleagues have undertaken to study the effects of disease-causing mutations in purified SOD in vitro. They chose four mutations that are quite different-e.g., several of the mutations alter the protein's structural flexibility, potentially affecting its conformation; another mutation introduces a hydrophobic region that has the potential to affect SOD dimerization.

In the current paper, Meiering and colleagues report that all four mutations lead to comparable decreases in the thermal stability of the protein and increases in the rate of experimentally (guanidinium Cl) induced unfolding. These results support the idea that SOD mutations of several types tip the balance in favor of unfolded or improperly folded forms of the protein that are more likely to aggregate. More support for this notion came from experiments in which aggregation was induced by trifluoroethanol (TFE) or by heat. Whereas wild-type SOD is highly stable and not easy to induce into aggregates, the SOD mutations led to aggregates under both manipulations. The morphologic characteristics of these aggregates were very similar to those seen in familial ALS patients and transgenic models. The process apparently involves a transition from small amorphous species to fibrils.

"Our data suggest that the different specific effects of SOD mutations may all lead to a common first step in [familial] ALS disease, namely, the aggregation of mutant SOD. SOD aggregation may increase because the mutant proteins have decreased stability, increased unfolding rate, and/or decreased folding rate...." conclude the authors.-Hakon Heimer.

Reference:
Stathopulos PB, Rumfeldt JAO, Scholz GA, Irani RA, Frey HE, Hallewell RA, Lepock JR, Meiering EM. Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7021-6. Epub 2003 May 28. Abstract

 
Comments on News and Primary Papers
  Comment by:  Roland Pochet
Submitted 8 June 2003  |  Permalink Posted 9 June 2003
  I recommend the Primary Papers

The concept of mutated SOD1 aggregate formation was previously evoked, but this article gives experimental evidence supporting this hypothesis. It remains now to explain why not all motoneurons (i.e. oculomotor nucleus) are not impaired.

View all comments by Roland Pochet
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad